AI assistant
Strategic Partners A/S Director's Dealing 2020
3411_rpt_2020-03-04_9bbee727-faf9-47d8-ba96-b6dec9b2e030.html
Director's Dealing
Open in viewerOpens in your device viewer
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
**Orphazyme A/S
Company announcement**
No. 24/2020
Company Registration No. 32266355
Copenhagen, Denmark, March 4, 2020 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:
1 Details of the Reporting Person / Closely Associated Person
a) Name
Anders Vadsholt
2 Reason for the notification
a) Position/status
Chief Financial Officer
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Purchase of shares
c) Price(s) and volume(s)
| Price (s) | Volume(s) | |
| DKK | 107 | 1,500 |
d) Aggregated information
Aggregated volume: 1,500
Aggregated price: DKK 160,500
Price per share (volume weighted average): DKK 107
e) Date of the transaction
2 March 2020, 11:29 UTC
f) Place of the transaction
Nasdaq Copenhagen A/S - XCSE
For additional information, please contact
Orphazyme A/S
Anders Vadsholt, CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.
Forward-looking statement
This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Attachment